[Recurrence or therapeutic resistance of acute myelogenous leukemia. Effect of mitoxantrone and cytosine arabinoside].
Adult patients with relapsed and refractory acute myelogenous leukemia usually demand further therapy aimed at achieving remission. The physician knows that life expectancy is limited. Care must be taken to choose a cytotoxic regimen where the potential gains outweigh the risks. Mitoxantrone and cytosine arabinoside were given in combination to 19 patients. Six achieved complete remission and increased survival. The side effects were acceptable.
Evensen
S A
SA
Brinch
L
L
Wisløff
F
F
D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D003561:Cytarabine / Q000008:administration & dosage*; D004351:Drug Resistance; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage*; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000401:mortality
D003561:Cytarabine; D008942:Mitoxantrone
Residiv eller behandlingsresistens av akutt myelogen leukemi. Effekt av mitoksantron og cytosin arabinosid.